FDA approval is just around
Who we are
We are a molecular diagnostics company developing and commercializing a pipeline of proprietary products for the screening and diagnosis of cancer.
Our products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients.
Our lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A..
Our technology and products have been validated through multiple partnerships with leading global diagnostic companies and testing laboratories.
We are an international company with operations in Europe and the U.S.A.
Epigenomics: US study suggests blood-based Septin9 CRC screening could save lives and be health-economically beneficial
CRC screening with blood-based Septin9 tests has potential to improve screening uptake and adherence rates
Septin9 testing could decrease colorectal cancer (CRC) incidence by 41% and CRC mortality by 61% at optimal screening uptake rates
Septin9 based screening shown to be cost-effective over no screening
Berlin, Germany, and U.S.A., July 22, 2013 - Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced findings from a health economic study by Prof. Uri Ladabaum, M.D., M.S., et al. from the Division of Gastroenterology and Hepatology, Stanford University School of Medicine, USA.